The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings

Clicks: 304
ID: 119650
2012
Division of Viral Hepatitis, Centers for Disease Control and Prevention.
Reference Key
db2012annalsthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Rein DB;Smith BD;Wittenborn JS;Lesesne SB;Wagner LD;Roblin DW;Patel N;Ward JW;Weinbaum CM;;
Journal annals of internal medicine
Year 2012
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/22056542
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support u.s. gov't aged middle aged united states / epidemiology P.H.S. sensitivity and specificity Cohort Studies contraindications computer simulation markov chains cost-benefit analysis bryce d smith cindy m weinbaum hepatitis c antibodies / blood* chronic / diagnosis* ribavirin / therapeutic use antiviral agents / therapeutic use mass screening / economics* interferon-alpha / therapeutic use david b rein chronic / mortality pmid:22056542 pmc5484577 doi:10.7326/0003-4819-156-4-201202210-00378 chronic / drug therapy primary health care / economics* quality-adjusted life years

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.